Adam Havey Insider Trading $EBS Emergent BioSolutions Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Adam Havey.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Adam Havey. Adam Havey is EVP, BioDefense Division in Emergent BioSolutions Inc. ($EBS) and EVP, Biodefense Divison in Emergent BioSolutions Inc. ($EBS) and EVP, Business Operations in Emergent BioSolutions Inc. ($EBS) and SVP, BioDefense Divison in Emergent BioSolutions Inc. ($EBS).
Adam Havey in Emergent BioSolutions Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Adam Havey: EVP, Business Operations, EVP, Biodefense Divison, EVP, BioDefense Division, SVP, BioDefense Divison
Holdings: 35,203 shares
Current Value: $1,033,208
Latest Transaction: Feb 11 2021
$EBS Market Capitalization: $1.21B
$EBS Previous Close: $29.35
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Adam Havey in Emergent BioSolutions Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11 2021 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Payment of Exercise | F | 123.45 | 2,183 | 269,491 | 33,020 | 35.2 K to 33 K (-6.20 %) |
| Feb 11 2021 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Grant | A | 0.00 | 2,518 | 0 | 35,203 | 32.7 K to 35.2 K (+7.70 %) |
| Apr 21 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | S | 30.86 | 17,009 | 524,898 | 80,384 | |
| Apr 21 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | S | 26.45 | 20,414 | 539,950 | 97,393 | |
| Apr 21 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 69.00 | 17,009 | 1,173,621 | 34,256 | 51.3 K to 34.3 K (-33.18 %) |
| Apr 21 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Buy | M | 30.86 | 17,009 | 524,898 | 51,265 | 34.3 K to 51.3 K (+49.65 %) |
| Apr 21 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 65.00 | 20,414 | 1,326,910 | 34,256 | 54.7 K to 34.3 K (-37.34 %) |
| Apr 21 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Buy | M | 26.45 | 20,414 | 539,950 | 54,670 | 34.3 K to 54.7 K (+59.59 %) |
| Apr 08 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 60.00 | 3,730 | 223,800 | 34,256 | 38 K to 34.3 K (-9.82 %) |
| Apr 08 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 60.00 | 4,242 | 254,520 | 37,986 | 42.2 K to 38 K (-10.05 %) |
| Feb 27 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | A | 61.44 | 22,784 | 1,399,849 | 43,105 | |
| Feb 27 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | A | 61.44 | 22,784 | 1,399,849 | 43,105 | |
| Feb 27 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Payment of Exercise | F | 58.42 | 409 | 23,894 | 42,228 | 42.6 K to 42.2 K (-0.96 %) |
| Feb 27 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Payment of Exercise | F | 58.42 | 409 | 23,894 | 42,228 | 42.6 K to 42.2 K (-0.96 %) |
| Feb 27 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Payment of Exercise | F | 59.91 | 484 | 28,996 | 42,637 | 43.1 K to 42.6 K (-1.12 %) |
| Feb 27 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Payment of Exercise | F | 59.91 | 484 | 28,996 | 42,637 | 43.1 K to 42.6 K (-1.12 %) |
| Feb 27 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Payment of Exercise | F | 59.91 | 513 | 30,734 | 43,121 | 43.6 K to 43.1 K (-1.18 %) |
| Feb 27 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Payment of Exercise | F | 59.91 | 513 | 30,734 | 43,121 | 43.6 K to 43.1 K (-1.18 %) |
| Feb 27 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Grant | A | 0.00 | 5,697 | 0 | 43,634 | 37.9 K to 43.6 K (+15.02 %) |
| Feb 27 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Grant | A | 0.00 | 5,697 | 0 | 43,634 | 37.9 K to 43.6 K (+15.02 %) |
| Feb 27 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Grant | A | 0.00 | 5,697 | 0 | 37,937 | 32.2 K to 37.9 K (+17.67 %) |
| Feb 27 2020 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Grant | A | 0.00 | 5,697 | 0 | 37,937 | 32.2 K to 37.9 K (+17.67 %) |
| Mar 13 2019 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 56.93 | 2,430 | 138,340 | 32,240 | 34.7 K to 32.2 K (-7.01 %) |
| Mar 04 2019 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 58.20 | 2,024 | 117,797 | 34,670 | 36.7 K to 34.7 K (-5.52 %) |
| Mar 04 2019 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 57.92 | 1,019 | 59,022 | 36,694 | 37.7 K to 36.7 K (-2.70 %) |
| Feb 28 2019 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | A | 61.01 | 20,321 | 1,239,784 | 20,321 | |
| Feb 28 2019 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Payment of Exercise | F | 58.71 | 812 | 47,673 | 37,713 | 38.5 K to 37.7 K (-2.11 %) |
| Feb 28 2019 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Payment of Exercise | F | 57.98 | 409 | 23,714 | 38,525 | 38.9 K to 38.5 K (-1.05 %) |
| Feb 28 2019 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Grant | A | 0.00 | 5,081 | 0 | 38,934 | 33.9 K to 38.9 K (+15.01 %) |
| Feb 28 2019 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Grant | A | 0.00 | 5,081 | 0 | 33,853 | 28.8 K to 33.9 K (+17.66 %) |
| Feb 28 2019 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Payment of Exercise | F | 61.01 | 481 | 29,346 | 28,772 | 29.3 K to 28.8 K (-1.64 %) |
| Nov 05 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | M | 25.62 | 6,168 | 158,024 | 0 | |
| Nov 05 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | M | 25.62 | 2,011 | 51,522 | 6,168 | |
| Nov 05 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 64.50 | 6,168 | 397,836 | 29,253 | 35.4 K to 29.3 K (-17.41 %) |
| Nov 05 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Buy | M | 25.62 | 6,168 | 158,024 | 35,421 | 29.3 K to 35.4 K (+21.09 %) |
| Nov 05 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 63.50 | 2,011 | 127,699 | 29,253 | 31.3 K to 29.3 K (-6.43 %) |
| Nov 05 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Buy | M | 25.62 | 2,011 | 51,522 | 31,264 | 29.3 K to 31.3 K (+6.87 %) |
| Oct 19 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | M | 25.62 | 314 | 8,045 | 8,179 | |
| Oct 19 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 61.50 | 314 | 19,311 | 29,253 | 29.6 K to 29.3 K (-1.06 %) |
| Oct 19 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Buy | M | 25.62 | 314 | 8,045 | 29,567 | 29.3 K to 29.6 K (+1.07 %) |
| Oct 17 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | M | 25.62 | 3,840 | 98,381 | 8,493 | |
| Oct 17 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | M | 25.62 | 6,165 | 157,947 | 12,333 | |
| Oct 17 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | M | 25.62 | 6,165 | 157,947 | 18,498 | |
| Oct 17 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | M | 25.62 | 6,165 | 157,947 | 24,663 | |
| Oct 17 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 63.50 | 3,840 | 243,840 | 29,253 | 33.1 K to 29.3 K (-11.60 %) |
| Oct 17 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Buy | M | 25.62 | 3,840 | 98,381 | 33,093 | 29.3 K to 33.1 K (+13.13 %) |
| Oct 17 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 61.50 | 6,165 | 379,148 | 29,253 | 35.4 K to 29.3 K (-17.41 %) |
| Oct 17 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Buy | M | 25.62 | 6,165 | 157,947 | 35,418 | 29.3 K to 35.4 K (+21.07 %) |
| Oct 17 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 60.67 | 661 | 40,103 | 29,253 | 29.9 K to 29.3 K (-2.21 %) |
| Oct 17 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 60.03 | 6,165 | 370,081 | 29,914 | 36.1 K to 29.9 K (-17.09 %) |
| Oct 17 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Buy | M | 25.62 | 6,165 | 157,947 | 36,079 | 29.9 K to 36.1 K (+20.61 %) |
| Oct 17 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 60.15 | 6,165 | 370,855 | 29,914 | 36.1 K to 29.9 K (-17.09 %) |
| Oct 17 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Buy | M | 25.62 | 6,165 | 157,947 | 36,079 | 29.9 K to 36.1 K (+20.61 %) |
| Mar 13 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 52.82 | 5,842 | 308,574 | 29,914 | 35.8 K to 29.9 K (-16.34 %) |
| Mar 13 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Payment of Exercise | F | 51.84 | 974 | 50,492 | 35,756 | 36.7 K to 35.8 K (-2.65 %) |
| Mar 09 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | M | 22.03 | 6,573 | 144,803 | 0 | |
| Mar 09 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Payment of Exercise | F | 50.43 | 2,843 | 143,372 | 36,730 | 39.6 K to 36.7 K (-7.18 %) |
| Mar 09 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Buy | M | 22.03 | 6,573 | 144,803 | 39,573 | 33 K to 39.6 K (+19.92 %) |
| Mar 01 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | A | 49.64 | 20,145 | 999,998 | 20,145 | |
| Mar 01 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 49.50 | 1,898 | 93,951 | 33,000 | 34.9 K to 33 K (-5.44 %) |
| Mar 01 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Payment of Exercise | F | 49.97 | 811 | 40,526 | 34,898 | 35.7 K to 34.9 K (-2.27 %) |
| Mar 01 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Payment of Exercise | F | 49.64 | 409 | 20,303 | 35,709 | 36.1 K to 35.7 K (-1.13 %) |
| Mar 01 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Grant | A | 0.00 | 5,036 | 0 | 36,118 | 31.1 K to 36.1 K (+16.20 %) |
| Mar 01 2018 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Grant | A | 0.00 | 5,036 | 0 | 31,082 | 26 K to 31.1 K (+19.34 %) |
| Sep 29 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | M | 22.03 | 7,885 | 173,707 | 0 | |
| Sep 29 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 39.50 | 7,885 | 311,458 | 26,046 | 33.9 K to 26 K (-23.24 %) |
| Sep 29 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Buy | M | 22.03 | 7,885 | 173,707 | 33,931 | 26 K to 33.9 K (+30.27 %) |
| Sep 12 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Option Exercise | M | 22.03 | 7,885 | 173,707 | 7,885 | |
| Sep 12 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Sell | S | 37.06 | 7,885 | 292,243 | 26,046 | 33.9 K to 26 K (-23.24 %) |
| Sep 12 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Business Opera ... | Buy | M | 22.03 | 7,885 | 173,707 | 33,931 | 26 K to 33.9 K (+30.27 %) |
| Apr 04 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Sell | S | 28.62 | 11,419 | 326,808 | 26,046 | 37.5 K to 26 K (-30.48 %) |
| Mar 16 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Gift | G | 0.00 | 1,800 | 0 | 37,465 | 39.3 K to 37.5 K (-4.58 %) |
| Mar 10 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Payment of Exercise | F | 31.05 | 1,624 | 50,425 | 39,265 | 40.9 K to 39.3 K (-3.97 %) |
| Mar 10 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Payment of Exercise | F | 30.98 | 1,076 | 33,334 | 40,889 | 42 K to 40.9 K (-2.56 %) |
| Mar 02 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | A | 30.63 | 17,134 | 524,814 | 17,134 | |
| Mar 02 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Payment of Exercise | F | 30.63 | 938 | 28,731 | 41,965 | 42.9 K to 42 K (-2.19 %) |
| Mar 02 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Grant | A | 0.00 | 4,285 | 0 | 42,903 | 38.6 K to 42.9 K (+11.10 %) |
| Mar 02 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Grant | A | 0.00 | 4,285 | 0 | 38,618 | 34.3 K to 38.6 K (+12.48 %) |
| Jan 19 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | J | 30.86 | 1,495 | 46,136 | 17,009 | |
| Jan 19 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | J | 26.45 | 1,794 | 47,451 | 20,414 | |
| Jan 19 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | J | 25.62 | 2,709 | 69,405 | 30,828 | |
| Jan 19 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | J | 22.03 | 1,386 | 30,534 | 15,770 | |
| Jan 19 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | J | 22.03 | 577 | 12,711 | 6,573 | |
| Jan 19 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Sell | S | 29.75 | 8,438 | 251,001 | 34,333 | 42.8 K to 34.3 K (-19.73 %) |
| Jan 19 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Buy | J | 0.00 | 748 | 0 | 42,771 | 42 K to 42.8 K (+1.78 %) |
| Jan 19 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Buy | J | 0.00 | 599 | 0 | 42,023 | 41.4 K to 42 K (+1.45 %) |
| Jan 19 2017 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Buy | J | 0.00 | 452 | 0 | 41,424 | 41 K to 41.4 K (+1.10 %) |
| Mar 31 2016 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | M | 15.91 | 3,467 | 55,160 | 0 | |
| Mar 31 2016 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Buy | M | 15.91 | 3,467 | 55,160 | 40,972 | 37.5 K to 41 K (+9.24 %) |
| Mar 16 2016 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Sell | S | 33.96 | 1,658 | 56,306 | 37,505 | 39.2 K to 37.5 K (-4.23 %) |
| Mar 16 2016 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Sell | S | 33.96 | 2,701 | 91,726 | 39,163 | 41.9 K to 39.2 K (-6.45 %) |
| Mar 15 2016 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | M | 14.67 | 7,960 | 116,773 | 0 | |
| Mar 15 2016 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Payment of Exercise | F | 34.22 | 1,278 | 43,733 | 41,864 | 43.1 K to 41.9 K (-2.96 %) |
| Mar 15 2016 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Sell | S | 33.84 | 3,152 | 106,664 | 43,142 | 46.3 K to 43.1 K (-6.81 %) |
| Mar 15 2016 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Sell | S | 33.84 | 7,960 | 269,366 | 46,294 | 54.3 K to 46.3 K (-14.67 %) |
| Mar 15 2016 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Buy | M | 14.67 | 7,960 | 116,773 | 54,254 | 46.3 K to 54.3 K (+17.19 %) |
| Mar 11 2016 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Payment of Exercise | F | 34.38 | 1,480 | 50,882 | 46,294 | 47.8 K to 46.3 K (-3.10 %) |
| Mar 11 2016 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Payment of Exercise | F | 34.60 | 1,061 | 36,711 | 47,774 | 48.8 K to 47.8 K (-2.17 %) |
| Mar 03 2016 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | A | 33.83 | 15,514 | 524,839 | 15,514 | |
| Mar 03 2016 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Grant | A | 0.00 | 7,759 | 0 | 48,835 | 41.1 K to 48.8 K (+18.89 %) |
| Jun 26 2015 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | M | 18.90 | 10,238 | 193,498 | 0 | |
| Jun 26 2015 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Buy | M | 18.90 | 10,238 | 193,498 | 41,076 | 30.8 K to 41.1 K (+33.20 %) |
| Jun 17 2015 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | M | 15.83 | 9,773 | 154,707 | 0 | |
| Jun 17 2015 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | M | 14.67 | 15,919 | 233,532 | 7,960 | |
| Jun 17 2015 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Sell | S | 31.50 | 10,606 | 334,110 | 30,838 | 41.4 K to 30.8 K (-25.59 %) |
| Jun 17 2015 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Sell | S | 31.67 | 9,773 | 309,462 | 41,444 | 51.2 K to 41.4 K (-19.08 %) |
| Jun 17 2015 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Buy | M | 15.83 | 9,773 | 154,707 | 51,217 | 41.4 K to 51.2 K (+23.58 %) |
| Jun 17 2015 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Sell | S | 31.50 | 15,919 | 501,480 | 41,444 | 57.4 K to 41.4 K (-27.75 %) |
| Jun 17 2015 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Buy | M | 14.67 | 15,919 | 233,532 | 57,363 | 41.4 K to 57.4 K (+38.41 %) |
| Jun 02 2015 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Buy | P | 27.08 | 98 | 2,654 | 41,444 | 41.3 K to 41.4 K (+0.24 %) |
| Mar 12 2015 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | A | 28.99 | 18,620 | 539,794 | 18,620 | |
| Mar 12 2015 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Payment of Exercise | F | 28.67 | 785 | 22,506 | 41,073 | 41.9 K to 41.1 K (-1.88 %) |
| Mar 12 2015 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Payment of Exercise | F | 28.99 | 1,278 | 37,049 | 41,858 | 43.1 K to 41.9 K (-2.96 %) |
| Mar 12 2015 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Payment of Exercise | F | 29.00 | 1,535 | 44,515 | 43,136 | 44.7 K to 43.1 K (-3.44 %) |
| Mar 12 2015 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Grant | A | 0.00 | 9,313 | 0 | 44,671 | 35.4 K to 44.7 K (+26.34 %) |
| Oct 16 2014 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Grant | A | 18.44 | 290 | 5,348 | 35,358 | 35.1 K to 35.4 K (+0.83 %) |
| Mar 18 2014 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Payment of Exercise | F | 27.06 | 1,077 | 29,144 | 35,068 | 36.1 K to 35.1 K (-2.98 %) |
| Mar 13 2014 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | M | 18.90 | 11,562 | 218,522 | 0 | |
| Mar 13 2014 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Sell | S | 27.50 | 11,562 | 317,955 | 36,145 | 47.7 K to 36.1 K (-24.24 %) |
| Mar 13 2014 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Buy | M | 18.90 | 11,562 | 218,522 | 47,707 | 36.1 K to 47.7 K (+31.99 %) |
| Mar 13 2014 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Payment of Exercise | F | 27.15 | 775 | 21,041 | 36,145 | 36.9 K to 36.1 K (-2.10 %) |
| Mar 12 2014 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | M | 15.83 | 4,887 | 77,361 | 4,887 | |
| Mar 12 2014 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | M | 15.91 | 6,933 | 110,304 | 0 | |
| Mar 12 2014 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Option Exercise | A | 28.09 | 28,119 | 789,863 | 28,119 | |
| Mar 12 2014 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Sell | S | 26.96 | 11,820 | 318,667 | 36,920 | 48.7 K to 36.9 K (-24.25 %) |
| Mar 12 2014 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Buy | M | 15.91 | 6,933 | 110,304 | 48,800 | 41.9 K to 48.8 K (+16.56 %) |
| Mar 12 2014 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Buy | M | 15.83 | 4,887 | 77,361 | 41,807 | 36.9 K to 41.8 K (+13.24 %) |
| Mar 12 2014 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Sell | S | 26.96 | 5,835 | 157,312 | 36,920 | 42.8 K to 36.9 K (-13.65 %) |
| Mar 12 2014 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Grant | A | 0.00 | 14,060 | 0 | 42,755 | 28.7 K to 42.8 K (+49.00 %) |
| Mar 12 2014 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, Biodefense Div ... | Payment of Exercise | F | 28.09 | 1,336 | 37,528 | 28,695 | 30 K to 28.7 K (-4.45 %) |
| Mar 18 2013 | EBS | Emergent BioSoluti ... | Havey Adam | SVP, Biodefense Div ... | Payment of Exercise | F | 14.46 | 1,046 | 15,125 | 36,823 | 37.9 K to 36.8 K (-2.76 %) |
| Mar 12 2013 | EBS | Emergent BioSoluti ... | Havey Adam | SVP, Biodefense Div ... | Option Exercise | A | 14.67 | 23,879 | 350,305 | 23,879 | |
| Mar 12 2013 | EBS | Emergent BioSoluti ... | Havey Adam | SVP, Biodefense Div ... | Grant | A | 0.00 | 11,939 | 0 | 31,077 | 19.1 K to 31.1 K (+62.38 %) |
| Mar 12 2013 | EBS | Emergent BioSoluti ... | Havey Adam | SVP, Biodefense Div ... | Payment of Exercise | F | 14.67 | 820 | 12,029 | 19,138 | 20 K to 19.1 K (-4.11 %) |
| Mar 12 2013 | EBS | Emergent BioSoluti ... | Havey Adam | SVP, Biodefense Div ... | Payment of Exercise | F | 15.22 | 642 | 9,771 | 19,958 | 20.6 K to 20 K (-3.12 %) |
| Mar 16 2012 | EBS | Emergent BioSoluti ... | Havey Adam | SVP, Biodefense Div ... | Option Exercise | A | 15.83 | 14,700 | 232,701 | 14,700 | |
| Mar 16 2012 | EBS | Emergent BioSoluti ... | Havey Adam | SVP, Biodefense Div ... | Payment of Exercise | F | 16.05 | 1,049 | 16,836 | 27,970 | 29 K to 28 K (-3.61 %) |
| Mar 16 2012 | EBS | Emergent BioSoluti ... | Havey Adam | SVP, Biodefense Div ... | Grant | A | 0.00 | 7,350 | 0 | 29,019 | 21.7 K to 29 K (+33.92 %) |
| Mar 12 2012 | EBS | Emergent BioSoluti ... | Havey Adam | SVP, Biodefense Div ... | Payment of Exercise | F | 14.49 | 535 | 7,752 | 14,319 | 14.9 K to 14.3 K (-3.60 %) |
| Mar 17 2011 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, BioDefense Div ... | Option Exercise | A | 24.15 | 20,380 | 492,177 | 20,380 | |
| Mar 17 2011 | EBS | Emergent BioSoluti ... | Havey Adam | EVP, BioDefense Div ... | Grant | A | 0.00 | 10,190 | 0 | 14,854 | 4.7 K to 14.9 K (+218.48 %) |
| Mar 10 2011 | EBS | Emergent BioSoluti ... | Havey Adam | SVP, BioDefense Div ... | Payment of Exercise | F | 21.15 | 536 | 11,336 | 4,664 | 4.1 K to 4.7 K (+12.98 %) |
Page: 1